뉴로진(주)
DE ˙ DB
SecurityDE:UU8 / Neurogene Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership656,572 shares
Latest Disclosed Value $ 13,525,383
Vanguard Group Inc reports 8.59% increase in ownership of UU8 / Neurogene Inc.

On January 29, 2026 - Vanguard Group Inc filed a 13F-HR form disclosing ownership of 656,572 shares of Neurogene Inc. (DE:UU8) valued at $13,525,383 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 7, 2025 disclosing 604,611 shares of Neurogene Inc.. This represents a change in shares of 8.59% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F NEUROGENE COM 64135M105 656,572 51,961 8.59 13,525 29.09 0.0002
2025-11-07 2025-09-30 13F NEUROGENE COM 64135M105 604,611 -5,726 -0.94 10,478 14.83 0.0002
2025-08-11 2025-06-30 13F NEUROGENE COM 64135M105 610,337 -7,598 -1.23 9,125 26.09 0.0001
2025-05-09 2025-03-31 13F NEUROGENE COM 64135M105 617,935 49,919 8.79 7,236 -44.27 0.0001
2025-02-11 2024-12-31 13F NEUROGENE COM 64135M105 568,016 -8,144 -1.41 12,985 -46.29 0.0002
2024-11-13 2024-09-30 13F NEUROGENE COM 64135M105 576,160 12,635 2.24 24,176 17.89 0.0004
2024-08-13 2024-06-30 13F NEUROGENE COM 64135M105 563,525 56,042 11.04 20,507 -20.61 0.0004
2024-05-10 2024-03-31 13F NEUROGENE COM 64135M105 507,483 457,062 906.49 25,831 2,543.81 0.0005
2024-03-11 2023-12-31 13F/A-1 NEUROGENE COM 64135M105 50,421 50,421 977 0.0000
2024-02-14 2023-12-31 13F NEUROGENE COM 64135M105 50,421 50,421 977 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.